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Background: Rocuronium produces injection pain in 50-80% of treated patients. Therefore, a variety of 
pretreatments have been attempted to reduce this issue. We evaluated the efficacy of 3 different doses of magnesium 
on the rocuronium injection pain and following hemodynamic changes by laryngoscopy and tracheal intubation 
(LTI).
Methods: Two hundreds patients, ASA I and II, undergoing general anesthesia for elective surgery were randomly 
divided to 4 groups: group 1, 2, 3, 4 received saline 5 ml, magnesium 5, 10 and 20 mg/kg prior to 0.6 mg/kg of 
rocuronium, respectively. Then, group 1 only was treated with esmolol (20 mg) before LTI. Pain intensity with 
rocuronium injection was assessed using a four-point scale according to patient’s movement. Cardiovascular 
responses at baseline, after induction, 1 minutes after LTI were determined. 
Results: Compared to saline, 10 and 20 mg/kg of magnesium significantly reduced the incidence of overall 
movement after rocuronium injection (34% and 36% in group 3 and 4, respectively vs. 76% in the group 1) (P < 0.0001). 
Generalized movement was seen in 4% of patients in groups 3 and 4, respectively. Compared to baseline values, 
diastolic blood pressure (DBP) immediately after LTI significantly increased within groups 1 and 2 (P < 0.001), but 
not within groups 3 and 4. 
Conclusions: Magnesium (10 and 20 mg/kg) prior to rocuronium was effective in attenuating rocuronium associated 
injection pain and cardiovascular changes by LTI. (Korean J Anesthesiol 2011; 60: 329-333)
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Introduction
    As a non-depolarizing muscle relaxant, rocuronium is 
useful for endotracheal intubation due to rapid onset time, 
but it produces injection pain, which is often associated with 
withdrawal movement of the injected hand or arm, in 50-
80% of injected patients [1]. Even in unconsciousness patients 
administered with anesthetic induction agents, rocuronium 
causes withdrawal movement, indicating intense pain [2]. 
Therefore, a variety of pretreatments have been attempted to 
reduce the rocuronium injection pain. Turan et al. [3] demon-
strated that a small dose of magnesium, average 7 mg/kg, 
reduced rocuronium injection pain effectively compared to 
lidocaine, sodium bicarbonate and alfentanil. 
    As a calcium channel blocker and a physiological antagonist 
of the N-methyl-D-aspartate (NMDA) receptors magnesium 
has reduced the anesthetic requirement during surgery and 
analgesics for postoperative pain control [4-7]. Although 
the exact mechanism is not clear, magnesium was also 
demonstrated to have a local analgesic effect in reducing 
injection pain by intravenous propofol [8,9] and rocuronium [3]. 
    After muscle relaxation with rocuronium, subsequent 
laryngoscopy and tracheal intubation (LTI) causes inevitable 
hemodynamic changes such as hypertension and tachycardia. 
Magnesium has also been suggested as a useful strategy in 
attenuating the adrenergic response to LTI [10,11]. However, in 
those studies, the authors used 50 or 60 mg/kg of magnesium 
to attenuate the hemodynamic response to LTI. That dose 
was much larger than the required amount of magnesium to 
reduce rocuronium injection pain. To date, few studies have 
investigated the effective doses of magnesium, which can 
attenuate both rocuronium injection pain and the following 
hemodynamic responses by LTI in general anesthesia.
    Therefore, the aim of this study was to evaluate the effectiveness 
of pretreatment with magnesium using doses of 5, 10, and 20 
mg/kg for both the prevention of rocuronium injection pain 
and the attenuation of the resulting hemodynamic response 
after LTI. 
Materials and Methods
    After obtaining our institutional ethics committee approval 
and patients’ written informed consent from each patient, 
200 America Society of Anesthesiologists physical status 
classification (ASA) I-II patients undergoing various elective 
surgeries with general anesthesia were randomly divided 
to 4 groups (all n = 50). They received normal saline 5 ml 
(group 1), magnesium sulfate 5, 10 and 20 mg/kg (groups 
2, 3 and 4), respectively, before rocuronium injection. To 
attenuate hemodynamic stimulation, 20 mg of esmolol 
(methyl 3-4-[2-hydroxy-3-(isopropylamino) propoxyphenyl] 
propionate hydrochloride) was given to group 1 before LTI. 
Randomization was conducted by computer-generated codes 
that were maintained in sequentially numbered envelopes. 
Exclusion criteria were prior use of calcium channel blockers, 
opioids and anticoagulants, pregnancy, known allergy to 
magnesium sulfate, disorders of cardiovascular, hepatic, renal, 
gastrointestinal and neurological diseases, morbid obesity, and 
difficult airway. No premedication was given to any patients. 
Before the induction of anesthesia standard monitoring of heart 
rate, non-invasive arterial pressure, ECG and arterial oxygen 
saturation was initiated. All patients had an 18 gauge IV catheter 
on the forearm and all drugs were administered near the IV 
catheter. Anesthesia was induced with propofol (2 mg/kg). After 
finding the abolished eyelid reflex, either normal saline 5 ml, 
or magnesium sulfate (5, 10, or 20 mg/kg) prior to 0.6 mg/kg of 
rocuronium was administered over one minute according to 
the assigned groups. Intravenous fluid infusion was occluded 
for 30 seconds after magnesium injection in all groups. Mask 
ventilation with sevoflurane in 100% oxygen was maintained for 
90 seconds after rocuronium injection, before LTI. Anesthesia 
after LTI was maintained with an end tidal sevoflurane con-
centration of 2-2.5% in a mixture of air and oxygen 50%.
    The patient’s response, as feeling of pain or discomfort, to 
intravenous rocuronium injection was assessed by observing 
patient’s movements, such as no movement (grade 0), move-
ment only wrist (grade 1), movement to the upper arm and 
shoulder of injected arm (grade 2) or generalized movements 
(grade 3).
    Hemodynamic variables such as systolic and diastolic blood 
pressure (SBP and DBP) and heart rate (HR) were recorded 
before the anesthetic induction (baseline value), before and 1 
min after tracheal intubation. 
    Data are expressed as means ± standard deviation (SD) or 
numbers of patients (percentages). Chi-square test or Fisher’s 
exact test was used for sex ratio and degree of withdrawal 
movements during injection of rocuronium among the groups. 
One way analysis of variance (ANOVA) for age, weight and 
height. A mixed linear model with Bonferroni’s correction 
within the groups and ANOVA with Bonferroni’s correction 
among the groups for hemodynamic changes at all study stages, 
were used. P < 0.05 was considered statistically significant. 
Results
    The demographic data were comparable among all groups 
(Table 1). Administration of magnesium at 10 and 20 mg/
kg significantly reduced the incidence of overall movement 
compared to the saline control after rocuronium administration 
(34% and 36% in the group 3 and 4, respectively vs. 76% in 331 www.ekja.org
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group 1) (P < 0.0001, for both comparisons). Withdrawal 
movement (grade 3), indicating severe pain, was seen in 4% of 
patients in both the magnesium 20 mg/kg and 10 mg/kg groups, 
respectively (both groups vs. saline, P < 0.05; both groups vs. 
magnesium 5 mg/kg, P < 0.05) (Table 2). 
    The mean baseline values for SBP, DBP and HR were 
comparable among the groups (Table 3). The SBP and DBP 
values following anesthetic induction before intubation were 
significantly lower compared to baseline values within the 
groups (P < 0.001 in each group). LTI caused no increase of 
SBP and DBP with the administration of magnesium sulfate 
at 10 mg/kg or 20 mg/kg prior to intubation, but significant 
increases in DBP were seen with administration of esmolol (20 
mg) or magnesium sulfate (5 mg/kg) compared to baseline 
values within each groups (P < 0.001). During anesthetic 
induction, HR was not different compared to baseline value 
within the groups. LTI caused a significant increase in HR 
compared to baseline values in all groups. Adverse effects 
such as severe hypotension or bradycardia was not seen in 
any patients following administration of either esmolol or 
magnesium at any doses before LTI. Although magnesium may 
potentiate neuromuscular blockade, it was assumed that the 
administration of magnesium sulfate (5, 10 or 20 mg/kg) did not 
prolong muscular relaxation in this study, because no patient 
was delayed to resume of ventilation at the end of surgery. 
Discussion
    In this study, we found that intravenous pretreatment with 10 
or 20 mg/kg of magnesium prior to rocuronium administration 
significantly alleviated rocuronium injection pain, 20 mg/
kg better than 10 mg/kg. In addition, magnesium at 10 or 20 
mg/kg prior to rocuronium provided stable blood pressures 
immediately after LTI. 
    Rocuronium is an attractive muscle relaxant due to rapid onset 
of action, and it works as fast as succinylcholine. However, high 
incidence of hand or limb withdrawal or generalized movement 
is seen, indicating injection pain, even under anesthesia, 
which can be a considerable drawback for rocuronium. The 
mechanism by which rocuronium causes injection pain is 
speculative [12,13]. Therefore, to overcome rocuronium induced 
withdrawal movement, a various studies using different drugs 
have been investigated [12,14-16]. In this study, 10 and 20 mg/
Table 1. Demographic Data 
Control  
(n = 50)
Mg 5 
(n = 50)
Mg 10 
(n = 50)
Mg 20 
(n = 50)
Gender (m/f)
Age (yr)
Weight (kg)
Height (cm)
24/26
41.7 ± 11.5
65.0 ± 13.3
164.8 ± 8.5
25/25
41.8 ± 12.4
64.9 ± 13.3
164.9 ± 9.3
23/27
39.8 ± 13.4
65.9 ± 12.1
165.6 ± 9.2
24/26
40.9 ± 14.9
63.4 ± 10.4
165.3 ± 10.5
Values are mean ± SD or numbers.  Mg 5, Mg 10 and Mg 20 indicate 
intravenous administration of the magnesium sulfate at doses of 5 
mg/kg, 10 mg/kg and 20 mg/kg, respectively, before rocuronium 
injection. 
Table 2. Assessment of Withdrawal Movement 
Control  
(n = 50)
Mg 5  
(n = 50)
Mg 10  
(n = 50)
Mg 20  
(n = 50)
Grade 0
Grade 1
Grade 2
Grade 3
Overall
12 (24%)
10 (20%)
19 (38%)
9 (18%)
38 (76%)
14 (28%)
   7 (14%)
16 (32%)
13 (26%)
36 (72%)
32 (64%)*,†
   8 (16%)
   8 (16%)
   2 (4%)*,†
18 (36%)*
33 (66%)*,†
10 (20%)
 5 (10%)*
   2 (4%)*,†
17 (34%)*
Values are numbers (%). Grade 0, 1, 2 and 3 indicate no movement, 
movement only wrist, movement to the upper arm and shoulder of 
injected arm and generalized movements, respectively. Mg 5, Mg 
10 and Mg 20 indicate intravenous administration of magnesium 
sulfate at doses of 5 mg/kg, 10 mg/kg and 20 mg/kg, respectively, 
prior to rocuronium injection. P < 0.05 was considered statistically 
significant. *P < 0.05 vs group 1. 
†P < 0.05 vs group 2.
Table 3.  Hemodynamic Data at All Observation Stages
Control
(n = 50)
Mg 5
(n = 50)
Mg 10
(n = 50)
Mg 20
(n = 50)
SBP (mmHg)
DBP (mmHg)
HR (beats/min)
Baseline
B-intubation
P-intubation 1 min
Baseline
B-intubation
P-intubation 1 min
Baseline
B-intubation
P-intubation 1 min
133 ± 19
112 ± 17*
133 ± 21
73 ± 12
61 ± 12*
81 ± 19*
74 ± 13
77 ± 13
99 ± 19*
134 ± 18
115 ± 21*
139 ± 26
69 ± 11
59 ± 11*
80 ± 21*
74 ± 14
77 ± 13
108 ± 16*
133 ± 19
111 ± 16*
131 ± 22
72 ± 13
59 ± 13*
76 ± 18
75 ± 13
76 ± 10
102 ± 17*
134 ± 20
110 ± 20*
133 ± 21
71 ± 13
57 ± 14*
69 ± 15
77 ± 13
81 ± 15
105 ± 15*
Values are expressed as mean ± SD. B-intubation: before intubation. P-intubation: post intubation. SBP: systolic blood pressure. DBP: diastolic 
blood pressure. HR: heart rate. Mg 5, Mg 10 and Mg 20 indicate intravenous administration of magnesium sulfate at 5 mg/kg, 10 mg/kg and 
20 mg/kg, respectively, prior to rocuronium injection. P < 0.05 was considered statistically significant. *P < 0.05 vs baseline value within each 
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kg of magnesium significantly reduced the overall incidence 
of movements associated with intravenous rocuronium, when 
compared to the saline control group. Generalized movement, 
indicating severe pain, was found only in 4% of patients 
administered magnesium at 10 or 20 mg/kg. 
    Magnesium sulfate, known to be a natural calcium channel 
blocker, has shown to have antinociceptive effects via inhibition 
of calcium channels and NMDA receptors [5]. Therefore, 
magnesium has been considered as a useful anesthetic adjunct 
for intra- and postoperative analgesia in anesthetic practice 
[4,6,7]. The local analgesic effect of magnesium has also been 
suggested in previous studies. For example, magnesium 
reduced local injection pain associated with intravenous 
propofol [8,9] and rocuronium [3]. Agarwal et al. [8] suggested 
that pretreatment with 1 g of magnesium minimized propofol 
induced pain and was as effective as 40 mg of lidocaine. In 
another comparison study aiming to prevent the injection 
pain by rocuronium, 2 ml of 2.48 mmol magnesium was found 
to be as effective as 30 mg of lignocaine, 2 ml of 8.4% sodium 
bicarbonate or 1,000 μg of alfentanil [3]. However, since it has 
been suggested that pretreatment with magnesium itself causes 
pain [8], caution for slow administration of magnesium may 
be needed. But, administration of magnesium sulfate over one 
minute in this study did not demonstrate any pain on injection 
per se as well as circulatory collapse.
    LTI after intubating dose of rocuronium produces marked 
increase in BP and HR due to catecholamine release. Because 
hemodynamic changes by LTI may be associated with 
serious medical conditions, various techniques including 
administration of magnesium, to attenuate the adrenergic 
responses by LTI have been investigated [10,11,17]. 
Pretreatment with intravenous magnesium (40 mg/kg) was 
reported as a helpful adjunct in reducing hemodynamic 
responses after succinylcholine facilitated tracheal intubation 
[17]. Further 60 mg of magnesium sulfate effectively attenuated 
the catecholamine release and hemodynamic response 
after non-depolarizing muscle relaxant induced LTI [10]. 
In compromised patients with coronary artery disease, 
magnesium at 50 mg/kg before the induction of anesthesia 
resulted in stable hemodynamic responses to LTI compared 
to lidocaine [11]. In the current study, administration of 
magnesium (10 or 20 mg/kg) prior to rocuronium to alleviate 
rocuronium injection pain also prevented the increase in 
blood pressure immediately after LTI. However, the significant 
increase in HR after LTI was not prevented with 10 or 20 mg/
kg of magnesium administration. Therefore, further studies 
to find the optimum dose of magnesium prior to rocuronium 
for inhibiting both rocuronium injection pain and the 
hemodynamic changes following LTI is needed. As a standard 
regimen to reduce hemodynamic changes by LTI in the control 
group, we used i.v. esmolol (20 mg) immediately before LTI [18]. 
A larger dose of esmolol was more effective in minimizing LTI 
induced responses, but it also showed a potential risk for severe 
bradycardia and hypotension in a low stress condition [19]. 
Therefore, we chose 20 mg of esmolol before LTI as a dose that 
would prevent severe hypertension and tachycardia without 
inducing significant hypotension and bradycardia. 
    In conclusion, although a dose that controlled both the 
pain related to rocuronium and the hemodynamic responses 
to intubation was not determined in this study, we found 
doses of magnesium (10 and 20 mg/kg) that alleviated the 
pain associated with rocuronium injection and as well as the 
changes in blood pressure after LTI. 
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